Скачать или смотреть Real-world outcomes of durvalumab ± tremelimumab in uHCC

Ciro Celsa, MD, PhD, University of Palermo, Palermo, Italy, discusses results from the DT-REAL study of durvalumab with or without tremelimumab in unresectable hepatocellular carcinoma (uHCC) according to HIMALAYA (NCT03298451) eligibility criteria. Patients who met trial criteria experienced longer survival and improved outcomes compared with those outside the criteria, with response and disease control rates consistent with previous data. Safety findings showed manageable toxicity, with most adverse events low grade. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.